Skip to search formSkip to main contentSkip to account menu

AC-T Regimen

Known as: AC-T, AC-Taxol Regimen 
A chemotherapy regimen consisting of doxorubucin hydrochloride (Adriamycin) and cyclophosphamide, followed by paclitaxel (Taxol), administered on… 
National Institutes of Health

Related topics

Related topics

4 relations
CyclophosphamideDoxorubicinPaclitaxelinvasive breast cancer

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Impact of treatment regimen on acute care use during and after adjuvant chemotherapy for early-stage breast cancer
PurposeThe Oncology Care Model was developed, in part, to reduce acute care use during the 6 months after chemotherapy initiation… 
2017
2017
Improving pathological response in locally advanced triple negative breast cancer: Comparison between CbD and AC-T regimens.
585Background: Pathological complete response (pCR) is a well-known surrogate for DFS and OS in triple negative breast cancer… 
2013
2013
Comparison of neoadjuvant adriamycin and docetaxel versus adriamycin, cyclophosphamide followed by paclitaxel in patients with operable breast cancer
Purpose Neoadjuvant chemotherapy is the standard treatment for patients with locally advanced breast cancer and is increasingly… 
2013
2013
유방암 환자에서 Adriamycin/docetaxel (AD) 과 Adriamycin/cyclophosphamide (AC-T) 선행항암화학요법의 비교
2011
2011
Efficacy results of node-negative HER2-amplified breast cancer subset from BCIRG 006 study: A phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC-T) with…
553 Background: Trastuzumab-chemotherapy-based adjuvant therapy (AC-TH or TCH) provide significant improvement in disease-free… 
2010
2010
EXPRESSÃO DE MARCADORES MOLECULARES PREDITIVOS DE RESPOSTA À TERAPÊUTICA NEOADJUVANTE EM CÂNCER DE MAMA EM AMOSTRAS TUMORAIS
Expression of Molecular Markers Predictive to Neoadjuvant Therapeutic Response in Breast Cancer in Tumor Samples. Justificative… 
2008
2008
A multicenter study of 3 docetaxel regimens with bevacizumab as adjuvant therapy for breast cancer (BC): Preliminary results
575 Background: Docetaxel-containing early stage BC regimens have demonstrated improvements in both disease-free and overall… 
Review
2008
Review
2008
Delivered relative dose intensity and febrile neutropenia rate with common adjuvant chemotherapy regimens: A review
11505 Background: Adjuvant chemotherapy for early-stage breast cancer decreases the risk of recurrence and improves survival… 
2006
2006
Docetaxel, carboplatin and trastuzumab (TCH) and doxorubicin/cyclophosphamide followed by docetaxel/trastuzumab (AC-TH) produce superior disease-free survival (DFS) compared to AC-T in patients (pts…
Review
2005
Review
2005
Change in Cycle 1 to Cycle 2 Haematological Counts Predicts Toxicity in Older Patients with Breast Cancer Receiving Adjuvant Chemotherapy
PurposeTo determine the association between changes in complete blood counts and grade 3 or 4 toxicities from cycle 1 to cycle 2… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)